B activation induced by LPS and was associated with decreased proteasome
activity in rat primary macrophage culture.
OBJECTIVES: In these studies, we determined whether acute experimental exposure to two different aerosols altered white blood cell (WBC) or red blood cell (RBC) proteasome
activity in human subjects.
The principle conclusion of the study was that plitidepsin, in combination with proteasome
inhibitors, has the potential to provide a therapeutic alternative for multiple myeloma in light of the observed high antitumoral response and lack of impact on bone.
Marizomib is a novel, brain-penetrant proteasome
inhibitor, which inhibits all three proteasome
activities following quercetin or rutin treatment were significantly augmented in comparison with non-treated cells.
Iceni Pharmaceuticals is planning a Phase II safety/efficacy trial of Cilcane starting in 2017 aimed at relapsed refractory patients who have already received one prior therapy of proteasome
plays an important role in virus life cycle.
Oleuropein activates the proteasome
, the natural recycling system of skin cells to help reduce existing levels of AGE.
Clearance of oxidatively modified proteins most often occurs through the proteasome
They will work to identify compounds capable of inhibiting proteasome
activity within the cells of malaria parasites, the action that is so critical to the parasite's survival.
is a primary multi catalytic-protease-complex for selective degradation of more than 80% intracellular proteins.
Bortezomib is a reversible proteasome
inhibitor, currently approved by US FDA for use in multiple myeloma and mantle cell lymphoma.
Topics to be discussed include deubiquitinating enzymes as drug targets, novel drug targets in the ubiquitin system, ubiquitin-like modifications, ubiquitin pathways in neurobiology, ubiquitin proteasome
system and oncology, and proteasome
structure and function.
Let's first take a look at one of the primary underlying causes of skin aging: loss of function of the proteasome
The multi-center study with MLN9708, an investigational, oral proteasome
inhibitor, will be conducted in Europe and North America.